Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FibroGen Presents Late-Breaker Abstract Results on Associations between Hemoglobin Levels and Cardiovascular Outcomes in Roxadustat-Treated Patients with Anemia of Chronic Kidney Disease (CKD)

GlobeNewswire October 22, 2020

FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined

GlobeNewswire October 14, 2020

New Ventures Funds Rebrands as Scientia Ventures

PR Newswire October 2, 2020

FibroGen Appoints Percy Carter, MBA, PhD, as Chief Scientific Officer

GlobeNewswire September 8, 2020

FibroGen to Present at Upcoming Investor Conferences

GlobeNewswire September 1, 2020

FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy

GlobeNewswire August 11, 2020

FibroGen Reports Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020

FibroGen Announces New Appointments to its Board of Directors

GlobeNewswire August 6, 2020

FibroGen to Report Second Quarter 2020 Financial Results

GlobeNewswire July 23, 2020

FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

GlobeNewswire June 23, 2020

FibroGen Appoints Thane Wettig as Chief Commercial Officer

GlobeNewswire June 22, 2020

FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress

GlobeNewswire June 8, 2020

FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19

GlobeNewswire June 8, 2020

FibroGen to Present at Upcoming Investor Conferences

GlobeNewswire May 27, 2020

European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat

PR Newswire May 20, 2020

FibroGen to Present at Bank of America Securities 2020 Health Care Conference

GlobeNewswire May 8, 2020

FibroGen Reports First Quarter 2020 Financial Results

GlobeNewswire May 7, 2020

FibroGen To Report First Quarter 2020 Financial Results

GlobeNewswire April 24, 2020

FibroGen Reports UK Court Ruling

GlobeNewswire April 20, 2020

FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire March 2, 2020